Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

To the Editor: We describe two cases of panniculitis apparently caused by dasatinib. In one, management after the diagnosis of the panniculitis allowed dasatinib therapy to be continued. In the first case, a 55-year-old woman (Patient 1) presented in the chronic phase of chronic myelogenous leukemia (CML) and did not have a major cytogenetic response (defined by the presence of the Philadelphia chromosome in <35 percent of cells in metaphase) to imatinib mesylate at a dose of 800 mg daily. She was known to have the activation-loop mutation H396R, which is associated with resistance to imatinib.1 She entered a phase . . .